secwatch.observer — SEC 8-K summary
======================================

Issuer:     Adicet Bio, Inc. (ACET)
CIK:        0001720580
Form:       8-K
Filed at:   2023-08-09T23:59:59+00:00
Accession:  0000950170-23-040617
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Adicet Q2 net loss $32.4M; ADI-001 shows 71% ORR, 63% CR in Phase 1 NHL
-----------------------------------------------------------------------

- Q2 net loss $32.4M ($0.75/share) vs $22.5M ($0.56) in Q2 2022; R&D expenses rose to $28.4M.
- ADI-001 Phase 1 data: 71% ORR, 63% CR across all dose levels in heavily pretreated NHL (median 4 prior lines); no DLTs/GvHD.
- Plan to initiate pivotal Phase 2 study in post-CAR T LBCL under accelerated approval in 2024; expansion cohort EXPAND starting.
- IND for ADI-925 (solid tumors) expected H2 2023; IND for ADI-270 (renal cell carcinoma) expected H1 2024.
- Cash $205.5M as of June 30, 2023; runway into H1 2025. Appointed Katie Peng to Board in July.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1720580/000095017023040617/0000950170-23-040617-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1720580/000095017023040617/acet-20230809.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-040617

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer